The Truth Behind Phase 3 Hair Regrowth Claims: Hype Vs. Verified Dermatological Science
Prescription topicals require dedicated daily application, substantial financial commitments, and months of patience. Identifying appropriate candidates avoids both wasted capital and emotional disappointment.
Strong Candidates for Topical Antiandrogens:
- Patients at Norwood Scale Stage 2 to 3: Individuals noticing active temporal thinning who retain miniaturizing, visible hairs across the target area.
- Side-Effect Intolerant Patients: Individuals who experienced adverse endocrine, depressive, or sexual side effects on oral 5-alpha reductase inhibitors.
- Female Pattern Hair Loss Patients: Women with androgen-sensitive crown thinning where traditional oral antiandrogens present off-label safety concerns.
Poor Candidates Likely to Experience Disappointment:
- Advanced Norwood Stages (5 through 7): Scalp zones that have been completely bald and smooth for several years possess non-viable follicles that cannot respond to receptor blockers.
- Non-Androgenetic Alopecias: Individuals suffering from telogen effluvium, alopecia areata, or cicatricial (scarring) alopecias. Clascoterone does not modulate autoimmune or inflammatory scarring pathways.
- Inconsistent Users: Topical treatments demand strict twice-daily application. Discontinuing therapy causes DHT receptors to resume normal binding within weeks, shedding all preserved gains.
Tags:
